Synthetic biology is helping save sea life + What’s next for mRNA vaccines?

News, trends, and stories from the synthetic biology industry

Hi ,

SynBioBeta is hosting a special event on May 26th to answer all your burning biopharma questions. What’s the current state of CRISPR-based medicine? What new investors are entering the biopharma space? What’s next for mRNA vaccines? Get your tickets now with our limited early-bird special until April 1st! Interactive breakout sessions will bring you in-depth conversations addressing some of the biggest questions in synthetic biology today. Speakers include:

Join us TODAY at 8 am PST for the Synthetic Biology Breaking News conversation on Clubhouse. Speakers include:

Mike Kamdar is the CEO of the first enzymatic DNA synthesis company and will be talking about the latest technology about to sweep through the industry.
Ryan Cawood is the Founder and CEO of OXGENE, an organization that designs and develops scalable gene therapy technologies and has recently been acquired by WuXi AppTec for $135 million.

SynBioBeta: In-Depth

Synthetic Biology, A Tool For Marine Conservation?
For marine conservation efforts to succeed, it is necessary to find sustainable alternatives to ocean resources. New synthetic biology innovations could help protect key marine populations threatened by hidden consumer demands.

Funding news

ElevateBio, a biotech company focused on gene-based therapies, has raised a massive $525 million series C round of financing.
Congratulations to Daphne Koller, CEO of Insitro, for raising $400 million in a series C financing. She was the keynote at our 2019 event, Insitro is doing great work on machine learning-driven drug discovery and development.

Daphne Koller, CEO of Insitro

Graphite Bio, a gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, announced the close of an oversubscribed $150 million series B financing.
Delonix Bioworks, a biotechnology company developing next-generation vaccines with synthetic biology approaches, has recently closed a $14 million seed financing. Based in Shanghai, China, Delonix’s synthetic biology and antigen discovery platforms enable rational design and programming of bacteria into more safe and effective vaccines.
Deep Branch, a carbon dioxide recycling company, announced it has completed an €8M series A investment round.
Octarine Bio, a synthetic biology company developing biosynthetic platforms for cannabinoids, psychedelics and their novel improved derivatives, has announced it has extended its seed round financing, closed in November 2020, with an additional $1.2 million, bringing the total amount raised by the company to over $3 million.